Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2025
0mins
Source: Globenewswire
Clinical Trial Results: Data from Chemomab Therapeutics' Phase 2 SPRING trial presented at BSG Live’25 indicates that nebokitug, a novel treatment for primary sclerosing cholangitis (PSC), is well-tolerated and shows significant improvements in biomarkers related to disease progression, suggesting its potential as a disease-modifying therapy.
Next Steps for Development: The encouraging results support the advancement of nebokitug to a Phase 3 registration trial, aiming to become the first approved therapy for PSC, addressing a critical unmet medical need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
